Early life exposures and the risk of EoE and other EGIDs

This survey study asks the question are early life exposures, such as Cesarean delivery, lack of breast feeding, antibiotics in infancy, or lack of presence of pets, and other exposures associated with subsequent development of EoE or other EGIDs? We hypothesize that certain early life factors increase the risk of EGIDs.

New results presented at the DDW meeting in San Diego, California, May, 2022:

The aim of this study was to assess whether certain early life factors were associated with development of non-EoE EGIDs. To do this, we used data from EGID Partners, and compared people who have non-EoE EGIDs to those who do not. We were able to look at data from 61 people with a non-EoE EGID and 20 people without an EGID. For those people with an EGID, 14 had eosinophilic gastritis (EoG), 19 had eosinophilic enteritis (EoN), 6 had eosinophilic colitis (EoC), and 22 had multiple areas of overlap; additionally, 30 had esophageal involvement.

We found that relative to those without an EGID, people with a non-EoE EGID were more likely to have had mothers who experienced pregnancy-related complications (43% vs 13%; p=0.02). We also found that people with a non-EoE EGID were more likely to have been admitted to the neonatal intensive care unit (NICU) when they were born (20% vs 0%; p=0.03), and were more likely to have been given antibiotics in infancy (43% vs 10%; p=0.01).

You can view the poster that we presented with the data here, and the published abstract can be found at this link in the journal Gastroenterology.

Burden of disease for patients with EoE and other EGIDs

This survey study asks the question what is the patient-level burden of disease related to EoE and EGIDs? We hypothesize that patient-level burden will be more substantial than previously reported, as our data will take into account actual expenditures for all medical care, treatments, and procedures, as well as missed time from work for patients and care takers, which will be novel and patient-centric data.

New results presented at the ACG meeting in Charlotte, North Carolina, October, 2022:

The aim of this study was to determine the patient-reported health care burden of disease and costs related to care for non-EoE EGIDs. To do this, we analyzed data from a survey on patient-reported healthcare utilization over the prior year related to heath care visits and procedures, as well as out-of-pocket costs/payments, for patients with non-EoE EGIDs like eosinophilic gastritis (EoG), eosinophilic enteritis (EoN), and eosinophilic colitis (EoC).

We found that the burden of disease was high. The median number of health care visits over the prior year was 12 (IQR: 5-33; range 1-90), with a median of 5 outpatient doctor visits, 3 urgent care/ED visits or hospitalizations, and 2 endoscopy visits. The annual median costs directly to patients were $1000 (IQR: $100-$3570; range: 0-$100,400). Median costs for outpatient visits, testing, and medications were $250, $400, and $325, respectively.

You can view the poster that we presented with the data here, and the published abstract can be found at this link in American Journal of Gastroenterology.